A Cost-Effectiveness Analysis of Gemcitabine plus Cisplatin Versus Gemcitabine Alone for Treatment of Advanced Biliary Tract Cancer in Japan View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2016-10-26

AUTHORS

Ikuto Tsukiyama, Masayuki Ejiri, Yoshihiro Yamamoto, Haruhisa Nakao, Masashi Yoneda, Katsuhiko Matsuura, Ichiro Arakawa, Hiroko Saito, Tadao Inoue

ABSTRACT

OBJECTIVES: This study assessed the cost-effectiveness of combination treatment with gemcitabine and cisplatin compared to treatment with gemcitabine alone for advanced biliary tract cancer (BTC) in Japan. METHODS: A monthly transmitted Markov model of three states was constructed based on the Japan BT-22 trial. Transition probabilities among the health states were derived from a trial conducted in Japan and converted to appropriate parameters for our model. The associated cost components, obtained from a receipt-based survey undertaken at the Aichi Medical University Hospital, were those related to inpatient care, outpatient care, and treatment for BTC. Costs for palliative care and treatment of adverse events were obtained from the National Health Insurance price list. We estimated cost-effectiveness per quality-adjusted life year (QALY) at a time horizon of 36 months. An annual discount of 3 % for both cost and outcome was considered. RESULTS: The base case outcomes indicated that combination therapy was less cost-effective than monotherapy when the incremental cost-effectiveness ratio (ICER) was approximately 14 million yen per QALY gained. The deterministic sensitivity analysis of the ICER revealed that the ICER of the base case was robust. A probabilistic analysis conducted with 10,000-time Monte Carlo simulations demonstrated efficacy at the willingness to pay threshold of 6 million yen per QALY gained for approximately 33 % of the population. CONCLUSION: In Japan, combination therapy is less cost-effective than monotherapy for treating advanced BTC, regardless of the statistical significance of the two therapies. Useful information on the cost-effectiveness of chemotherapy is much needed for the treatment of advanced BTC in Japan. More... »

PAGES

326-332

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s12029-016-9885-6

DOI

http://dx.doi.org/10.1007/s12029-016-9885-6

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1043690830

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/27785685


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/14", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Economics", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1402", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Applied Economics", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biliary Tract Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cisplatin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cost-Benefit Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Deoxycytidine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Japan", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Faculty of Pharmacy, Meijo University, Nagoya, Japan", 
          "id": "http://www.grid.ac/institutes/grid.259879.8", 
          "name": [
            "Department of Pharmacy, Aichi Medical University Hospital, 1-1 Yazago Karimata, Nagakute-shi, Aichi 480-1195 Japan", 
            "Faculty of Pharmacy, Meijo University, Nagoya, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tsukiyama", 
        "givenName": "Ikuto", 
        "id": "sg:person.0732621330.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0732621330.08"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pharmacy, Aichi Medical University Hospital, 1-1 Yazago Karimata, Nagakute-shi, Aichi 480-1195 Japan", 
          "id": "http://www.grid.ac/institutes/grid.510308.f", 
          "name": [
            "Department of Pharmacy, Aichi Medical University Hospital, 1-1 Yazago Karimata, Nagakute-shi, Aichi 480-1195 Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ejiri", 
        "givenName": "Masayuki", 
        "id": "sg:person.07772367115.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07772367115.19"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pharmacy, Aichi Medical University Hospital, 1-1 Yazago Karimata, Nagakute-shi, Aichi 480-1195 Japan", 
          "id": "http://www.grid.ac/institutes/grid.510308.f", 
          "name": [
            "Department of Pharmacy, Aichi Medical University Hospital, 1-1 Yazago Karimata, Nagakute-shi, Aichi 480-1195 Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yamamoto", 
        "givenName": "Yoshihiro", 
        "id": "sg:person.01346022310.81", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346022310.81"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Gastroenterology, Department of Internal Medicine, Aichi Medical University, School of Medicine, Nagakute-shi, Japan", 
          "id": "http://www.grid.ac/institutes/grid.411234.1", 
          "name": [
            "Division of Gastroenterology, Department of Internal Medicine, Aichi Medical University, School of Medicine, Nagakute-shi, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nakao", 
        "givenName": "Haruhisa", 
        "id": "sg:person.0651550111.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0651550111.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Gastroenterology, Department of Internal Medicine, Aichi Medical University, School of Medicine, Nagakute-shi, Japan", 
          "id": "http://www.grid.ac/institutes/grid.411234.1", 
          "name": [
            "Division of Gastroenterology, Department of Internal Medicine, Aichi Medical University, School of Medicine, Nagakute-shi, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yoneda", 
        "givenName": "Masashi", 
        "id": "sg:person.013606074302.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013606074302.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pharmacy, Aichi Medical University Hospital, 1-1 Yazago Karimata, Nagakute-shi, Aichi 480-1195 Japan", 
          "id": "http://www.grid.ac/institutes/grid.510308.f", 
          "name": [
            "Department of Pharmacy, Aichi Medical University Hospital, 1-1 Yazago Karimata, Nagakute-shi, Aichi 480-1195 Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Matsuura", 
        "givenName": "Katsuhiko", 
        "id": "sg:person.01231411530.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01231411530.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Faculty of Pharmaceutical Science, Teikyo Heisei University, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.440938.2", 
          "name": [
            "Faculty of Pharmaceutical Science, Teikyo Heisei University, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Arakawa", 
        "givenName": "Ichiro", 
        "id": "sg:person.0762752760.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0762752760.28"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Faculty of Pharmacy, Meijo University, Nagoya, Japan", 
          "id": "http://www.grid.ac/institutes/grid.259879.8", 
          "name": [
            "Faculty of Pharmacy, Meijo University, Nagoya, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Saito", 
        "givenName": "Hiroko", 
        "id": "sg:person.01166251613.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01166251613.10"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "School of Pharmaceutical Sciences, Ohu University, Koriyama, Hukushima Japan", 
          "id": "http://www.grid.ac/institutes/grid.410777.2", 
          "name": [
            "School of Pharmaceutical Sciences, Ohu University, Koriyama, Hukushima Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Inoue", 
        "givenName": "Tadao", 
        "id": "sg:person.011256274510.26", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011256274510.26"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/sj.bjc.6605211", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027066974", 
          "https://doi.org/10.1038/sj.bjc.6605211"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12029-010-9242-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047218048", 
          "https://doi.org/10.1007/s12029-010-9242-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6603648", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026959106", 
          "https://doi.org/10.1038/sj.bjc.6603648"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6605779", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037652459", 
          "https://doi.org/10.1038/sj.bjc.6605779"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2016-10-26", 
    "datePublishedReg": "2016-10-26", 
    "description": "OBJECTIVES: This study assessed the cost-effectiveness of combination treatment with gemcitabine and cisplatin compared to treatment with gemcitabine alone for advanced biliary tract cancer (BTC) in Japan.\nMETHODS: A monthly transmitted Markov model of three states was constructed based on the Japan BT-22 trial. Transition probabilities among the health states were derived from a trial conducted in Japan and converted to appropriate parameters for our model. The associated cost components, obtained from a receipt-based survey undertaken at the Aichi Medical University Hospital, were those related to inpatient care, outpatient care, and treatment for BTC. Costs for palliative care and treatment of adverse events were obtained from the National Health Insurance price list. We estimated cost-effectiveness per quality-adjusted life year (QALY) at a time horizon of 36\u00a0months. An annual discount of 3\u00a0% for both cost and outcome was considered.\nRESULTS: The base case outcomes indicated that combination therapy was less cost-effective than monotherapy when the incremental cost-effectiveness ratio (ICER) was approximately 14 million yen per QALY gained. The deterministic sensitivity analysis of the ICER revealed that the ICER of the base case was robust. A probabilistic analysis conducted with 10,000-time Monte Carlo simulations demonstrated efficacy at the willingness to pay threshold of 6 million yen per QALY gained for approximately 33\u00a0% of the population.\nCONCLUSION: In Japan, combination therapy is less cost-effective than monotherapy for treating advanced BTC, regardless of the statistical significance of the two therapies. Useful information on the cost-effectiveness of chemotherapy is much needed for the treatment of advanced BTC in Japan.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s12029-016-9885-6", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1297362", 
        "issn": [
          "1941-6628", 
          "1941-6636"
        ], 
        "name": "Journal of Gastrointestinal Cancer", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "48"
      }
    ], 
    "keywords": [
      "quality-adjusted life years", 
      "incremental cost-effectiveness ratio", 
      "cost-effectiveness analysis", 
      "cost-effectiveness ratio", 
      "deterministic sensitivity analyses", 
      "base case outcomes", 
      "price lists", 
      "life years", 
      "cost components", 
      "time horizon", 
      "annual discount", 
      "advanced biliary tract cancer", 
      "health states", 
      "biliary tract cancer", 
      "yen", 
      "base case", 
      "time Monte Carlo simulations", 
      "sensitivity analysis", 
      "cost", 
      "tract cancer", 
      "combination therapy", 
      "discount", 
      "inpatient care", 
      "Japan", 
      "outpatient care", 
      "willingness", 
      "Markov model", 
      "Aichi Medical University Hospital", 
      "Medical University Hospital", 
      "Monte Carlo simulations", 
      "adverse events", 
      "horizon", 
      "palliative care", 
      "University Hospital", 
      "Carlo simulations", 
      "combination treatment", 
      "gemcitabine", 
      "model", 
      "therapy", 
      "statistical significance", 
      "probabilistic analysis", 
      "monotherapy", 
      "care", 
      "treatment", 
      "cancer", 
      "useful information", 
      "trials", 
      "survey", 
      "analysis", 
      "outcomes", 
      "state", 
      "chemotherapy", 
      "hospital", 
      "cisplatin", 
      "months", 
      "efficacy", 
      "information", 
      "case outcomes", 
      "population", 
      "years", 
      "threshold", 
      "significance", 
      "study", 
      "cases", 
      "events", 
      "transition", 
      "list", 
      "appropriate parameters", 
      "ratio", 
      "components", 
      "simulations", 
      "parameters", 
      "Japan BT-22 trial", 
      "BT-22 trial", 
      "receipt-based survey", 
      "National Health Insurance price list", 
      "Health Insurance price list", 
      "Insurance price list", 
      "Cisplatin Versus Gemcitabine", 
      "Versus Gemcitabine"
    ], 
    "name": "A Cost-Effectiveness Analysis of Gemcitabine plus Cisplatin Versus Gemcitabine Alone for Treatment of Advanced Biliary Tract Cancer in Japan", 
    "pagination": "326-332", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1043690830"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s12029-016-9885-6"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "27785685"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s12029-016-9885-6", 
      "https://app.dimensions.ai/details/publication/pub.1043690830"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:36", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_698.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s12029-016-9885-6"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12029-016-9885-6'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12029-016-9885-6'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12029-016-9885-6'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12029-016-9885-6'


 

This table displays all metadata directly associated to this object as RDF triples.

263 TRIPLES      22 PREDICATES      119 URIs      107 LITERALS      16 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s12029-016-9885-6 schema:about N07acff812e47413b91a6457622a93a3d
2 N08371ed0789d4c0d9ebf411bc8229c5d
3 N241de655c5d4453493ee38a56bcab32f
4 N78b35a6f87d2490bb582112c52f9d60a
5 N79545bb8d63846a6be21567ca0721d2d
6 N9ef958b03673429788e12009361e946a
7 Nc4a8a7e1648e4e87ac7f5bb20b8ee0e1
8 Nc8d2ba2d40f4449986459aead369d099
9 Nd144923ccea74daca39b334f0292f5f1
10 anzsrc-for:14
11 anzsrc-for:1402
12 schema:author Nb2fcba41ce364a428f9cf1c4b10bca50
13 schema:citation sg:pub.10.1007/s12029-010-9242-0
14 sg:pub.10.1038/sj.bjc.6603648
15 sg:pub.10.1038/sj.bjc.6605211
16 sg:pub.10.1038/sj.bjc.6605779
17 schema:datePublished 2016-10-26
18 schema:datePublishedReg 2016-10-26
19 schema:description OBJECTIVES: This study assessed the cost-effectiveness of combination treatment with gemcitabine and cisplatin compared to treatment with gemcitabine alone for advanced biliary tract cancer (BTC) in Japan. METHODS: A monthly transmitted Markov model of three states was constructed based on the Japan BT-22 trial. Transition probabilities among the health states were derived from a trial conducted in Japan and converted to appropriate parameters for our model. The associated cost components, obtained from a receipt-based survey undertaken at the Aichi Medical University Hospital, were those related to inpatient care, outpatient care, and treatment for BTC. Costs for palliative care and treatment of adverse events were obtained from the National Health Insurance price list. We estimated cost-effectiveness per quality-adjusted life year (QALY) at a time horizon of 36 months. An annual discount of 3 % for both cost and outcome was considered. RESULTS: The base case outcomes indicated that combination therapy was less cost-effective than monotherapy when the incremental cost-effectiveness ratio (ICER) was approximately 14 million yen per QALY gained. The deterministic sensitivity analysis of the ICER revealed that the ICER of the base case was robust. A probabilistic analysis conducted with 10,000-time Monte Carlo simulations demonstrated efficacy at the willingness to pay threshold of 6 million yen per QALY gained for approximately 33 % of the population. CONCLUSION: In Japan, combination therapy is less cost-effective than monotherapy for treating advanced BTC, regardless of the statistical significance of the two therapies. Useful information on the cost-effectiveness of chemotherapy is much needed for the treatment of advanced BTC in Japan.
20 schema:genre article
21 schema:inLanguage en
22 schema:isAccessibleForFree true
23 schema:isPartOf N58ae6f9cb1ad404d9440184b3b0839bf
24 Nf152c451a0cd4bbfa46cfcb3a9753144
25 sg:journal.1297362
26 schema:keywords Aichi Medical University Hospital
27 BT-22 trial
28 Carlo simulations
29 Cisplatin Versus Gemcitabine
30 Health Insurance price list
31 Insurance price list
32 Japan
33 Japan BT-22 trial
34 Markov model
35 Medical University Hospital
36 Monte Carlo simulations
37 National Health Insurance price list
38 University Hospital
39 Versus Gemcitabine
40 advanced biliary tract cancer
41 adverse events
42 analysis
43 annual discount
44 appropriate parameters
45 base case
46 base case outcomes
47 biliary tract cancer
48 cancer
49 care
50 case outcomes
51 cases
52 chemotherapy
53 cisplatin
54 combination therapy
55 combination treatment
56 components
57 cost
58 cost components
59 cost-effectiveness analysis
60 cost-effectiveness ratio
61 deterministic sensitivity analyses
62 discount
63 efficacy
64 events
65 gemcitabine
66 health states
67 horizon
68 hospital
69 incremental cost-effectiveness ratio
70 information
71 inpatient care
72 life years
73 list
74 model
75 monotherapy
76 months
77 outcomes
78 outpatient care
79 palliative care
80 parameters
81 population
82 price lists
83 probabilistic analysis
84 quality-adjusted life years
85 ratio
86 receipt-based survey
87 sensitivity analysis
88 significance
89 simulations
90 state
91 statistical significance
92 study
93 survey
94 therapy
95 threshold
96 time Monte Carlo simulations
97 time horizon
98 tract cancer
99 transition
100 treatment
101 trials
102 useful information
103 willingness
104 years
105 yen
106 schema:name A Cost-Effectiveness Analysis of Gemcitabine plus Cisplatin Versus Gemcitabine Alone for Treatment of Advanced Biliary Tract Cancer in Japan
107 schema:pagination 326-332
108 schema:productId N1ba173c84aaa4c97acdb8d3519403f92
109 N2cd04d17c4874ed1b306060308e91299
110 N6d54b22c70b54f96b0f3f7643efb4f7a
111 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043690830
112 https://doi.org/10.1007/s12029-016-9885-6
113 schema:sdDatePublished 2021-12-01T19:36
114 schema:sdLicense https://scigraph.springernature.com/explorer/license/
115 schema:sdPublisher N60ba98dc46ed461e83f241ef87440baa
116 schema:url https://doi.org/10.1007/s12029-016-9885-6
117 sgo:license sg:explorer/license/
118 sgo:sdDataset articles
119 rdf:type schema:ScholarlyArticle
120 N07acff812e47413b91a6457622a93a3d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Cost-Benefit Analysis
122 rdf:type schema:DefinedTerm
123 N08371ed0789d4c0d9ebf411bc8229c5d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Cisplatin
125 rdf:type schema:DefinedTerm
126 N1ba173c84aaa4c97acdb8d3519403f92 schema:name doi
127 schema:value 10.1007/s12029-016-9885-6
128 rdf:type schema:PropertyValue
129 N241de655c5d4453493ee38a56bcab32f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Deoxycytidine
131 rdf:type schema:DefinedTerm
132 N2cd04d17c4874ed1b306060308e91299 schema:name pubmed_id
133 schema:value 27785685
134 rdf:type schema:PropertyValue
135 N2e92622b57cc48c29cf5bacd725201e1 rdf:first sg:person.011256274510.26
136 rdf:rest rdf:nil
137 N4cca91d9590b42b6b5d5cbdfa99d4707 rdf:first sg:person.01166251613.10
138 rdf:rest N2e92622b57cc48c29cf5bacd725201e1
139 N58ae6f9cb1ad404d9440184b3b0839bf schema:volumeNumber 48
140 rdf:type schema:PublicationVolume
141 N60ba98dc46ed461e83f241ef87440baa schema:name Springer Nature - SN SciGraph project
142 rdf:type schema:Organization
143 N60bc9cef727547fdbbd3d2bd519bea25 rdf:first sg:person.01231411530.33
144 rdf:rest Nb44a95a5b4fc4f7c88c1d144ff9c0022
145 N6d54b22c70b54f96b0f3f7643efb4f7a schema:name dimensions_id
146 schema:value pub.1043690830
147 rdf:type schema:PropertyValue
148 N77d225838a29405885a598861735af65 rdf:first sg:person.0651550111.35
149 rdf:rest Nd87dd3e54ceb482fbf9d5197ee7c71ac
150 N78b35a6f87d2490bb582112c52f9d60a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Male
152 rdf:type schema:DefinedTerm
153 N79545bb8d63846a6be21567ca0721d2d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Female
155 rdf:type schema:DefinedTerm
156 N91da8b4b54864798b3ba99c1ee82ecb1 rdf:first sg:person.01346022310.81
157 rdf:rest N77d225838a29405885a598861735af65
158 N9ef958b03673429788e12009361e946a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Humans
160 rdf:type schema:DefinedTerm
161 Nb2fcba41ce364a428f9cf1c4b10bca50 rdf:first sg:person.0732621330.08
162 rdf:rest Ncd843029613b4e55b43134445b186e6a
163 Nb44a95a5b4fc4f7c88c1d144ff9c0022 rdf:first sg:person.0762752760.28
164 rdf:rest N4cca91d9590b42b6b5d5cbdfa99d4707
165 Nc4a8a7e1648e4e87ac7f5bb20b8ee0e1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Japan
167 rdf:type schema:DefinedTerm
168 Nc8d2ba2d40f4449986459aead369d099 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
169 schema:name Antineoplastic Agents
170 rdf:type schema:DefinedTerm
171 Ncd843029613b4e55b43134445b186e6a rdf:first sg:person.07772367115.19
172 rdf:rest N91da8b4b54864798b3ba99c1ee82ecb1
173 Nd144923ccea74daca39b334f0292f5f1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Biliary Tract Neoplasms
175 rdf:type schema:DefinedTerm
176 Nd87dd3e54ceb482fbf9d5197ee7c71ac rdf:first sg:person.013606074302.33
177 rdf:rest N60bc9cef727547fdbbd3d2bd519bea25
178 Nf152c451a0cd4bbfa46cfcb3a9753144 schema:issueNumber 4
179 rdf:type schema:PublicationIssue
180 anzsrc-for:14 schema:inDefinedTermSet anzsrc-for:
181 schema:name Economics
182 rdf:type schema:DefinedTerm
183 anzsrc-for:1402 schema:inDefinedTermSet anzsrc-for:
184 schema:name Applied Economics
185 rdf:type schema:DefinedTerm
186 sg:journal.1297362 schema:issn 1941-6628
187 1941-6636
188 schema:name Journal of Gastrointestinal Cancer
189 schema:publisher Springer Nature
190 rdf:type schema:Periodical
191 sg:person.011256274510.26 schema:affiliation grid-institutes:grid.410777.2
192 schema:familyName Inoue
193 schema:givenName Tadao
194 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011256274510.26
195 rdf:type schema:Person
196 sg:person.01166251613.10 schema:affiliation grid-institutes:grid.259879.8
197 schema:familyName Saito
198 schema:givenName Hiroko
199 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01166251613.10
200 rdf:type schema:Person
201 sg:person.01231411530.33 schema:affiliation grid-institutes:grid.510308.f
202 schema:familyName Matsuura
203 schema:givenName Katsuhiko
204 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01231411530.33
205 rdf:type schema:Person
206 sg:person.01346022310.81 schema:affiliation grid-institutes:grid.510308.f
207 schema:familyName Yamamoto
208 schema:givenName Yoshihiro
209 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346022310.81
210 rdf:type schema:Person
211 sg:person.013606074302.33 schema:affiliation grid-institutes:grid.411234.1
212 schema:familyName Yoneda
213 schema:givenName Masashi
214 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013606074302.33
215 rdf:type schema:Person
216 sg:person.0651550111.35 schema:affiliation grid-institutes:grid.411234.1
217 schema:familyName Nakao
218 schema:givenName Haruhisa
219 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0651550111.35
220 rdf:type schema:Person
221 sg:person.0732621330.08 schema:affiliation grid-institutes:grid.259879.8
222 schema:familyName Tsukiyama
223 schema:givenName Ikuto
224 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0732621330.08
225 rdf:type schema:Person
226 sg:person.0762752760.28 schema:affiliation grid-institutes:grid.440938.2
227 schema:familyName Arakawa
228 schema:givenName Ichiro
229 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0762752760.28
230 rdf:type schema:Person
231 sg:person.07772367115.19 schema:affiliation grid-institutes:grid.510308.f
232 schema:familyName Ejiri
233 schema:givenName Masayuki
234 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07772367115.19
235 rdf:type schema:Person
236 sg:pub.10.1007/s12029-010-9242-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047218048
237 https://doi.org/10.1007/s12029-010-9242-0
238 rdf:type schema:CreativeWork
239 sg:pub.10.1038/sj.bjc.6603648 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026959106
240 https://doi.org/10.1038/sj.bjc.6603648
241 rdf:type schema:CreativeWork
242 sg:pub.10.1038/sj.bjc.6605211 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027066974
243 https://doi.org/10.1038/sj.bjc.6605211
244 rdf:type schema:CreativeWork
245 sg:pub.10.1038/sj.bjc.6605779 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037652459
246 https://doi.org/10.1038/sj.bjc.6605779
247 rdf:type schema:CreativeWork
248 grid-institutes:grid.259879.8 schema:alternateName Faculty of Pharmacy, Meijo University, Nagoya, Japan
249 schema:name Department of Pharmacy, Aichi Medical University Hospital, 1-1 Yazago Karimata, Nagakute-shi, Aichi 480-1195 Japan
250 Faculty of Pharmacy, Meijo University, Nagoya, Japan
251 rdf:type schema:Organization
252 grid-institutes:grid.410777.2 schema:alternateName School of Pharmaceutical Sciences, Ohu University, Koriyama, Hukushima Japan
253 schema:name School of Pharmaceutical Sciences, Ohu University, Koriyama, Hukushima Japan
254 rdf:type schema:Organization
255 grid-institutes:grid.411234.1 schema:alternateName Division of Gastroenterology, Department of Internal Medicine, Aichi Medical University, School of Medicine, Nagakute-shi, Japan
256 schema:name Division of Gastroenterology, Department of Internal Medicine, Aichi Medical University, School of Medicine, Nagakute-shi, Japan
257 rdf:type schema:Organization
258 grid-institutes:grid.440938.2 schema:alternateName Faculty of Pharmaceutical Science, Teikyo Heisei University, Tokyo, Japan
259 schema:name Faculty of Pharmaceutical Science, Teikyo Heisei University, Tokyo, Japan
260 rdf:type schema:Organization
261 grid-institutes:grid.510308.f schema:alternateName Department of Pharmacy, Aichi Medical University Hospital, 1-1 Yazago Karimata, Nagakute-shi, Aichi 480-1195 Japan
262 schema:name Department of Pharmacy, Aichi Medical University Hospital, 1-1 Yazago Karimata, Nagakute-shi, Aichi 480-1195 Japan
263 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...